AR046102A1 - Forma de dosificacion farmaceutica de liberacion prolongada - Google Patents
Forma de dosificacion farmaceutica de liberacion prolongadaInfo
- Publication number
- AR046102A1 AR046102A1 ARP040103689A ARP040103689A AR046102A1 AR 046102 A1 AR046102 A1 AR 046102A1 AR P040103689 A ARP040103689 A AR P040103689A AR P040103689 A ARP040103689 A AR P040103689A AR 046102 A1 AR046102 A1 AR 046102A1
- Authority
- AR
- Argentina
- Prior art keywords
- prolonged release
- pharmaceutical dosage
- dosage forms
- dosage form
- venlafaxine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formas de dosificación farmacéuticas de liberación prolongada, para la administración oral de fármacos a mamíferos, por ejemplo, seres humanos. Más específicamente, se refiere a formas de dosificación de fármacos hidrosolubles tales como la venlafaxina, formas enantioméricas (R o S) de la venlafaxina, metabolitos de la venlafaxina tales como la O-desmetilvenlafaxina (ODV) o formas enantioméricas (R o S) de dichos metabolitos en donde las formas de dosificación tienen un perfil de liberación prolongada cuando se toman por vía oral. Procedimientos para la preparación de dichas formas de dosificación y métodos para su uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03256438A EP1523979A1 (en) | 2003-10-13 | 2003-10-13 | Extended release pharmaceutical dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046102A1 true AR046102A1 (es) | 2005-11-23 |
Family
ID=34354596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103689A AR046102A1 (es) | 2003-10-13 | 2004-10-12 | Forma de dosificacion farmaceutica de liberacion prolongada |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050129762A1 (es) |
EP (2) | EP1523979A1 (es) |
KR (1) | KR20060108675A (es) |
CN (1) | CN1889935A (es) |
AR (1) | AR046102A1 (es) |
AU (1) | AU2004283436A1 (es) |
CA (1) | CA2546199A1 (es) |
CO (1) | CO5690532A2 (es) |
CR (1) | CR8403A (es) |
EC (1) | ECSP066566A (es) |
NO (1) | NO20062142L (es) |
PE (1) | PE20050439A1 (es) |
TW (1) | TW200518788A (es) |
WO (1) | WO2005039527A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
JP2008525313A (ja) * | 2004-12-27 | 2008-07-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬の安定化方法 |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
EP2114455A4 (en) * | 2006-12-20 | 2010-03-17 | Mylan Pharmaceuticals Ulc | PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT |
AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
US8178133B2 (en) | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium compositions and uses thereof |
JP2010522216A (ja) | 2007-03-22 | 2010-07-01 | リュー,グオソン | マグネシウム組成物およびその使用 |
WO2011003045A1 (en) * | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL108838C (es) * | 1956-03-27 | |||
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
US5530013A (en) * | 1994-02-14 | 1996-06-25 | American Home Products Corporation | Venlafaxine in the inducement of cognition enhancement |
US5506270A (en) * | 1995-01-30 | 1996-04-09 | American Home Products Corporation | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women |
US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
US6033686A (en) * | 1998-10-30 | 2000-03-07 | Pharma Pass Llc | Controlled release tablet of bupropion hydrochloride |
US20030059466A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Delayed release tablet of venlafaxin |
DE10208335A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
AR039165A1 (es) * | 2002-03-28 | 2005-02-09 | Synthon Bv | Venlafaxina base |
US20030190351A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon Bv | Extended release venlafaxine formulations |
IL149055A0 (en) * | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
ATE457166T1 (de) * | 2003-07-24 | 2010-02-15 | Wockhardt Ltd | Orale zusammensetzungen zur behandlung von diabetes |
-
2003
- 2003-10-13 EP EP03256438A patent/EP1523979A1/en not_active Withdrawn
-
2004
- 2004-10-11 WO PCT/EP2004/011339 patent/WO2005039527A2/en active Application Filing
- 2004-10-11 CA CA002546199A patent/CA2546199A1/en not_active Abandoned
- 2004-10-11 AU AU2004283436A patent/AU2004283436A1/en not_active Abandoned
- 2004-10-11 CN CNA2004800365221A patent/CN1889935A/zh active Pending
- 2004-10-11 KR KR1020067009322A patent/KR20060108675A/ko not_active Application Discontinuation
- 2004-10-11 TW TW093130742A patent/TW200518788A/zh unknown
- 2004-10-11 EP EP04790255A patent/EP1675575A2/en not_active Withdrawn
- 2004-10-12 PE PE2004000984A patent/PE20050439A1/es not_active Application Discontinuation
- 2004-10-12 AR ARP040103689A patent/AR046102A1/es unknown
- 2004-10-13 US US10/964,012 patent/US20050129762A1/en not_active Abandoned
-
2006
- 2006-05-12 NO NO20062142A patent/NO20062142L/no not_active Application Discontinuation
- 2006-05-12 EC EC2006006566A patent/ECSP066566A/es unknown
- 2006-05-12 CO CO06045403A patent/CO5690532A2/es not_active Application Discontinuation
- 2006-05-12 CR CR8403A patent/CR8403A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1523979A1 (en) | 2005-04-20 |
EP1675575A2 (en) | 2006-07-05 |
NO20062142L (no) | 2006-07-06 |
ECSP066566A (es) | 2006-10-17 |
CN1889935A (zh) | 2007-01-03 |
WO2005039527A3 (en) | 2006-04-06 |
CR8403A (es) | 2006-10-26 |
CA2546199A1 (en) | 2005-05-06 |
CO5690532A2 (es) | 2006-10-31 |
US20050129762A1 (en) | 2005-06-16 |
PE20050439A1 (es) | 2005-08-03 |
TW200518788A (en) | 2005-06-16 |
KR20060108675A (ko) | 2006-10-18 |
WO2005039527A2 (en) | 2005-05-06 |
AU2004283436A1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
AR048963A1 (es) | Formulaciones de interferon de hidrogel de poloxamero | |
BRPI0906197B8 (pt) | forma de administração em formato de tira | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
DE602006015592D1 (de) | Orodispersible pharmazeutische Zusammensetzung für die orale, oromukosale oder sublinguale Verabreichung von Agomelatin | |
CU20080052A7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
BRPI0515070B8 (pt) | sistema de entrega de medicamentos auto-emulsificante de butilftalida e processo para a preparação do sistema de entrega de medicamentos auto-emulsificante de butilftalida | |
BRPI0512792A (pt) | formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol | |
BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
BRPI0608297A2 (pt) | composições de lipossomos | |
TW200616640A (en) | Novel pharmaceutical formulations of active principles | |
ECSP066566A (es) | Formas de dosificación farmacéutica de liberación extendida | |
CL2007001917A1 (es) | Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras. | |
BRPI0816320A2 (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação | |
BRPI0709057B8 (pt) | veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação | |
CR8371A (es) | Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas | |
CO2019000643A2 (es) | Formulaciones gastrorretentivas orales y usos de las mismas | |
DE602004011398D1 (de) | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 | |
BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
BRPI0516464B8 (pt) | método para a preparação de um produto farmacêutico | |
DE602004006860D1 (de) | Capsaicinoid enthaltende pharmazeutische zusammensetzung zur oralen verabreichung | |
DK2805723T3 (da) | Cladribin-regime til behandling af multipel sclerose | |
PL1742927T3 (pl) | Pochodne kwasu butanowego, sposoby ich otrzymywania, kompozycje farmaceutyczne zawierające takie pochodne i terapeutyczne zastosowanie takich pochodnych | |
BRPI0821454A2 (pt) | Formulação farmacêutica, excipiente para a preparação de formulação farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |